NCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
Clinical Trials
16 trialsNCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT04410367 2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2 Completed
NCT04750473 2025-01-17
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Emory University
Phase 1 Completed
NCT03707184 2024-11-29
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
University of Utah
Phase 2 Completed
NCT03926507 2024-10-09
F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery
M.D. Anderson Cancer Center
Phase NA Completed
NCT03868020 2024-03-28
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT04114370 2022-12-06
FACBC
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT03990285 2021-12-22
Axumin
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03930173 2021-05-05
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT03263780 2021-02-21
High Resolution PET-MRI Before Prostate Cancer HIFU
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03081884 2021-01-25
EDRN-FACBC
Emory University
Phase 2 Completed
NCT03264456 2020-03-09
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02443571 2018-12-19
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
Blue Earth Diagnostics
Completed
NCT03036943 2018-12-19
FRONTIER
University of Oxford
Phase NA Completed
NCT00562315 2016-06-21
FACBC PET/CT for Recurrent Prostate Cancer
Emory University
Phase 2 Completed